Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services (BDMS) to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Market Overview - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025. The specialty health check segment is the fastest-growing part, indicating strong demand for advanced and targeted screening solutions [1] Strategic Partnership - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer, to enhance early disease detection services across nearly 60 hospitals within the N Health network [2] Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3] Innovation in Testing - The new home test kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into one component, significantly reducing contamination and user error risks [3][4] Accessibility and Consumer Focus - The company aims to distribute these test kits through modern trade channels and pharmacies across Thailand, aligning with evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4]

Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Group 1: Strategic Partnership and Market Growth - The partnership aims to penetrate the rapidly growing health check market in Thailand, which is expected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025 [1] - The specialized health check segment is the fastest-growing part of the market, indicating strong demand for advanced and targeted screening solutions [1] Group 2: Cancer Screening Solutions - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear for gastric cancer and LUNGClear for lung cancer, to improve cancer treatment standards in the region [2] - Nearly 60 hospitals within the N Health network will adopt the cancer screening tests, supporting broader access to early disease detection services across Thailand and Southeast Asia [2] Group 3: Home Testing Kits Launch - The company announced the launch of new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand, following approvals from the Thai FDA [3] - These home test kits are the first of their kind in the Thai market, designed to integrate sample collection and testing into a single, user-friendly device, significantly reducing contamination and user error risks [3][4] Group 4: Accessibility and Consumer Engagement - The home test kits will be distributed through modern trade channels and pharmacies across Thailand, catering to evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4] - The launch emphasizes the company's mission to democratize early detection, empowering individuals with practical tools to manage their health and support the healthcare system through early intervention and increased disease awareness [4]

Core Viewpoint - The strategic partnership between MIRXES-B and N Health aims to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and improving patient outcomes in the region [1][2]. Group 1: Strategic Partnership - The partnership is established to leverage MIRXES-B's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer [2]. - The collaboration will introduce cancer screening tests across nearly 60 hospitals within the N Health network, supporting broader access to early disease detection services in Thailand and Southeast Asia [2]. - N Health aims to enhance its role in providing end-to-end healthcare solutions and expand the accessibility of advanced cancer screening nationwide, integrating cancer risk assessments into preventive care [2]. Group 2: Market Potential - Thailand's health check-up market is projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1]. - The increasing awareness of preventive healthcare and rising chronic disease prevalence create an ideal environment for adopting innovative diagnostic technologies like MIRXES-B's miRNA tests [1]. Group 3: New Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3]. - These home test kits are designed to complement the core miRNA cancer screening solutions and are the first of their kind in the Thai market, featuring an innovative single-device design that minimizes processing steps and reduces contamination risks [3][4]. - The distribution of these test kits will be through modern trade and pharmacy channels across Thailand, aligning with evolving consumer healthcare behaviors and increasing demand for preventive, self-diagnostic solutions [4].

Group 1 - MIRXES-B has established a strategic partnership with N Health to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step in early cancer detection and improving patient outcomes in the region [1] - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate of 9.2% starting from 2025, indicating strong demand for advanced and targeted screening solutions [1] - The partnership aims to leverage the increasing awareness of preventive healthcare and the rising prevalence of chronic diseases to create an ideal environment for adopting innovative diagnostic technologies like miRNA testing [1] Group 2 - The company launched a new series of home screening test kits in Thailand, including HELICORapid for detecting H. pylori infections and FITRapid for detecting fecal occult blood, both of which are significant cancer risk factors [2] - These home testing kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into a streamlined component, reducing processing steps and minimizing contamination risks [2] - The company aims to expand its sales and marketing efforts into the consumer sector, providing easy-to-use and hygienic home testing options while maintaining scientific rigor and user safety [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 自願性公告 於泰國的近期業務發展進程 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 與N HEALTH建立戰略夥伴關係 本公司董事（「董事」）會（「董事會」）宣佈，本公司已於2025年12月15日與N Health （「N Health」，為 一 家 醫 療 保 健 解 決 方 案 供 應 商 及 泰 國 最 大 醫 療 保 健 供 應 商 Bangkok Dusit Medical Services (BDMS) Group的成員公司）建立戰略夥伴關係（「戰 略夥伴關係」）。戰略夥伴關係旨在將先進的microRN ...